Press Release

The ADBC promotes Danish companies in the U.S., and American companies in Denmark. The Council, comprised of an estimated 60 Danish and American companies as members, is engaged in a range of activities targeted at obtaining an even more thriving American-Danish market place with increased trade and investment. The Council is administered through the Office of the Prime Minister of Denmark whose most recent visit to the U.S. included a tour of Novozymes' research facility in Davis, Calif., to learn more about bioenergy activities and promote commercial ties between Denmark and the United States.

"It is an honor to serve on the Council's board as it is representative of the cultures and the business markets in which Novozymes operates. And the significant similarities between Denmark and North Carolina are ever-growing. Both have become biotech havens and are recognized and respected within the industry for contributions made to biotechnology and innovation, stated Nagy. "And Novozymes wants to continue to foster those relationships," he concluded.

Nagy joined Novozymes, which has U.S. headquarters in North Carolina, in 1987 when the company was the enzyme division of Danish-based insulin manufacturer Novo Nordisk. Nagy has held a variety of management positions of increasing responsibility and prior to selection as president of Novozymes North America, served as vice president for production and global procurement for Novozymes A/S in Bagsværd, Denmark. Nagy currently serves on the governing body of the Industrial & Environmental Section of the Biotechnology Industry Organization (BIO).

Novozymes North America has recently been recognized by the NC Biotechnology Center as the state's leading industrial biotechnology company.

# # #

The American-Danish Business Council seeks to promote the exchange of experience and ideas on economic, policy and trade issues that affect both the United States and Denmark, such as: information technology and e-business; exports to and investments in the United States and wider Baltic Sea area; legal issues; product liability, standards, certification and approvals; taxes; intellectual property issues; branding and pricing issues; human resources and intercultural issues; and business and government contacts and partnerships.

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 4,000 people in 30 countries. Producing more than 100 types of enzymes and microorganisms and selling more than 600 products in 130 countries, Novozymes A/S B shares are listed on the Copenhagen Stock Exchange. For further company information, visit us at www.novozymes.com.